Neurothera Labs (FRA:C0A) Debt-to-EBITDA : N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C0A Neurothera Labs Inc FRA:C0A
31 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurothera Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.30 Mil. Neurothera Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.49 Mil. Neurothera Labs's annualized EBITDA for the quarter that ended in Dec. 2025 was €0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Neurothera Labs's Debt-to-EBITDA or its related term are showing as below:

FRA:C0A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.31   Med: 0   Max: 0
Current: -6.31
FRA:C0A's Debt-to-EBITDA is ranked worse than
100% of 682 companies
in the Drug Manufacturers industry
Industry Median: 1.63 vs FRA:C0A: -6.31

Neurothera Labs  (FRA:C0A) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Neurothera Labs Debt-to-EBITDA Related Terms

Neurothera Labs Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Debt-to-EBITDA Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Debt-to-EBITDA
0.00 0.00 0.00 0.00 0.00

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 N/A

FRA:C0A vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurothera Labs Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's Debt-to-EBITDA falls into.


FRA:C0A
31GF Score
Neurothera Labs Inc FRA:C0A
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Neurothera Labs's Debt-to-EBITDA for the fiscal year that ended in Jan. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.17
=0.00

Neurothera Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.304 + 0.494) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.

Neurothera Labs Business Description

Other Exchanges NTLX:Canada
Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score

Get the complete analysis for FRA:C0A

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price